Summary
MiraeAsset TIGER NASDAQ BIO ETF is an ETF - a fund traded on an exchange like a stock - run by Tiger ETF. Positions inside: 246. The ten largest make up 47% of the fund.
- Yearly costs
- 0.30%
- Fund size
- ₩103.2B
- Positions
- 246
- Dividends
- Reinvested
- Running since
- 2014
What speaks for it
- Costs of 0.30% a year are below the middle of comparable funds (0.43%).
- Average yearly growth over the last ten years: 12%.
- It has been running since 2014.
What to watch
- 98% of the fund is in one sector (Healthcare).
- 88% of the fund is in one country (United States).
- In the last five years its price once dropped by 31% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +1.2%
- 3 months
- +1.9%
- This year
- +16%
- 1 year
- +26%
- 3 years
- +94%
- 5 years
- +65%
- 10 years
- +203%
- Avg. market cap
- $82.7B
- P/E
- 29.0x
- Forward P/E
- 20.8x
- P/S
- 7.2x
- P/B
- 6.2x
- P/FCF
- 21.5x
- EV/EBITDA
- 21.8x
- Dividend yield
- 0.58%
- ROIC
- -2.7%
- ROE
- 7.5%
- Gross margin
- 70.5%
- Operating margin
- -16.3%
- Net margin
- -23.4%
- Payout ratio
- 16.8%
- Net debt/EBITDA
- 5.9x
- Beta
- 0.16
Weighted average of the 50 largest companies, which make up 79% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Moderately concentrated- 1 GIGilead Sciences GILD 8.4%
- 2 AMAmgen AMGN 8.1%
- 3 VRVertex Pharmaceuticals VRTX 7.7%
- 4 MRModerna MRNA 6.4%
- 5 RERegeneron Pharmaceuticals REGN 5.3%
- 6 ILIllumina ILMN 2.8%
- 7 RVRevolution Medicines RVMD 2.7%
- 8 BIBiogen BIIB 2.3%
- 9 ALAlnylam Pharmaceuticals ALNY 2.0%
- 10 RPRoyalty Pharma RPRX 1.8%
Positions in the fund: 246. The ten largest make up 47% of it.
Composition as of Oct 23, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 98%
- Other 2.4%
By country
- United States 88%
- Netherlands 1.9%
- Bermuda 1.7%
- Switzerland 1.5%
- Other countries 6.5%
By company size
- Mega cap 8.3%
- Large cap 62%
- Mid cap 22%
- Small cap 6.9%
- Micro cap 0.5%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (98%). Largest country: United States (88%). Largest size group: Large cap (62%).
What does it cost me?
Cheap- A year from ₩10,000
- ₩30.00
- Over 20 years
- ₩1,476
From every ₩10,000 invested the fund takes ₩30.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about ₩1,476.
How has it done?
Growing over the long run- A year on average, 10 years
- +12%
- Deepest drop
- -31%
- Yearly volatility
- 25%
Average yearly growth over the last ten years: 12%. Deepest drop in these years: 31% below the earlier high.
Does it pay dividends?
No, it reinvestsThe fund pays nothing out. What its holdings earn stays inside and shows in the price.
Is it easy to buy and sell?
- Traded a day
- ₩1.01B
- Shares a day
- 29K
On an average day about ₩1.01B of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 29.0
- Average Bulios Score
- 52 out of 100
Weight by Bulios Fair Price
- Undervalued 17%
- Fairly valued 22%
- Overvalued 61%
On average the companies inside trade for 29.0 times their yearly profit. By Fair Price, 61% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 79% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $580.1M | +42% | Reinvests | 96% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $81.8M | +35% | Pays out | 96% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $926.0M | +41% | Reinvests | 96% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.8B | +37% | Pays out | 83% |
BI BIB ProShares Ultra Nasdaq Biotechnology | United States | 1.17% | $94.9M | +69% | Pays out | 61% |
BB BBH VanEck Biotech ETF | United States | 0.35% | $502.1M | +42% | Pays out | 57% |
